AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3465258 — intervention group
Group type: COMPARATOR
Intervention: Diazepam alone or with fentanyl
Number of subjects: 0
Study 3465258 — intervention group
Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 0
Study 29490024 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte/Monocyte Apheresis (GMA) plus oral prednisone (40 mg/day and tapering)
Number of subjects: 123
Study 29490024 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisone alone
Number of subjects: 123
Study 29490024 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte/Monocyte Apheresis (GMA) plus oral prednisone (GMA group)
Number of subjects: 123
Study 29121226 — intervention group
Group type: EXPERIMENTAL
Intervention: OFDI-guided PCI
Number of subjects: 829
Study 29121226 — intervention group
Group type: COMPARATOR
Intervention: IVUS-guided PCI
Number of subjects: 829
Study 26717390 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafamostat mesilate (NM)
Number of subjects: 55
Study 24091500 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-residue breakfast
Number of subjects: 0
Study 24091500 — intervention group
Group type: COMPARATOR
Intervention: Standard clear-fluid diet
Number of subjects: 0
Study 21636268 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Laparoscopic Hysterectomy (TLH)
Number of subjects: 283
Study 17531309 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Word Form Area (VWFA) activation during processing of English words and meaningful symbols.
Number of subjects: 0
Study 17531309 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional connectivity analysis of VWFA during word processing.
Number of subjects: 0
Study 17531309 — intervention group
Group type: EXPERIMENTAL
Intervention: General activation of VWFA for symbolic stimuli.
Number of subjects: 0
Study 17531309 — intervention group
Group type: EXPERIMENTAL
Intervention: Broader brain activity correlated with VWFA.
Number of subjects: 0
Study 16405522 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy based on BNP levels
Number of subjects: 2213
Study 16405522 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP cut-off level of 1.25 pmol L(‐1)
Number of subjects: 2213
Study 16405522 — intervention group
Group type: COMPARATOR
Intervention: Control group (uneventful follow-up)
Number of subjects: 2213
Study 15327820 — intervention group
Group type: EXPERIMENTAL
Intervention: High Tech VR
Number of subjects: 2
Study 15327820 — intervention group
Group type: COMPARATOR
Intervention: Low Tech VR
Number of subjects: 2
Study 11037672 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory rehabilitation programme for mothers
Number of subjects: 0
Study 11037672 — intervention group
Group type: EXPERIMENTAL
Intervention: Utilisation of the health care system
Number of subjects: 0
Study 9288223 — intervention group
Group type: COMPARATOR
Intervention: pcV
Number of subjects: 53
Study 9288223 — intervention group
Group type: EXPERIMENTAL
Intervention: clindamycin
Number of subjects: 53
Study 7680832 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic porcine galanin (0.5 mg in 100 ml saline)
Number of subjects: 6
Study 7680832 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (100 ml saline)
Number of subjects: 6
Study 3554804 — intervention group
Group type: EXPERIMENTAL
Intervention: Bencyclane 200 mg b.i.d.
Number of subjects: 120
Study 3554804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 29708822 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg TID for 2 weeks (open-label treatment)
Number of subjects: 103
Study 29708822 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg TID for 2 weeks (double-blind treatment)
Number of subjects: 103
Study 29708822 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks (double-blind treatment)
Number of subjects: 103
Study 27924635 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive feedback
Number of subjects: 66
Study 27924635 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative feedback
Number of subjects: 66
Study 27924635 — intervention group
Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 66
Study 25887713 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex nursing care intervention of CAM
Number of subjects: 590
Study 25887713 — intervention group
Group type: COMPARATOR
Intervention: Usual nursing care (Control)
Number of subjects: 590
Study 24167181 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to monochlorophenoxy acid or ester herbicides
Number of subjects: 2885
Study 24167181 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to insecticides (aldicarb, dimethoate, phorate, petroleum oils)
Number of subjects: 2885
Study 24167181 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to adjuvant polyoxyethylene sorbitol
Number of subjects: 2885
Study 24167181 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to 2,6-dinitroaniline herbicides
Number of subjects: 2885
Study 24167181 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to herbicide oxyfluorfen
Number of subjects: 2885
Study 24167181 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to fungicide copper sulfate
Number of subjects: 2885
Study 24167181 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to chloroacetanilide herbicides
Number of subjects: 2885
Study 24167181 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to polyalkyloxy compounds used as adjuvants
Number of subjects: 2885
Study 24167181 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to insecticides (aldicarb, acephate)
Number of subjects: 2885
Study 24167181 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to adjuvant nonyl-phenoxy-poly(ethylene oxy)ethanol
Number of subjects: 2885
Study 21418448 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based environmental management in intervention blocks
Number of subjects: 59
Study 21418448 — intervention group
Group type: COMPARATOR
Intervention: Routine vector control activities in control blocks
Number of subjects: 59
Study 21418448 — intervention group
Group type: COMPARATOR
Intervention: Comparison of intervention vs control
Number of subjects: 59
Study 21418448 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected intervention blocks
Number of subjects: 59
Study 21418448 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based environmental management
Number of subjects: 59
Study 19563205 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion treatment
Number of subjects: 1076
Study 19563205 — intervention group
Group type: COMPARATOR
Intervention: Routine medicine treatment
Number of subjects: 1076
Study 17417987 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaceprol 1200 mg/day
Number of subjects: 167
Study 17417987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 15351584 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral pudendal nerve blockade with 10 mg of 1% prilocaine (group 1, n = 26)
Number of subjects: 51
Study 15351584 — intervention group
Group type: COMPARATOR
Intervention: Placebo control with 10 mL of 0.9 NaCl solution (group 2, n = 25)
Number of subjects: 51
Study 11496278 — intervention group
Group type: EXPERIMENTAL
Intervention: High end-diastolic blood flow velocities
Number of subjects: 45
Study 11496278 — intervention group
Group type: COMPARATOR
Intervention: Low end-diastolic blood flow velocities
Number of subjects: 45
Study 11496278 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum systolic and end-diastolic blood flow velocities
Number of subjects: 45
Study 9566835 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-linolenic and linoleic acid (1 g/day of each fatty acid) for 6 weeks
Number of subjects: 15
Study 9566835 — intervention group
Group type: COMPARATOR
Intervention: Oleic acid and linoleic acid for 6 weeks
Number of subjects: 15
Study 7997384 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg alone
Number of subjects: 7
Study 7997384 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole 200 mg with concomitant ddI 300 mg
Number of subjects: 7
Study 2454893 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine
Number of subjects: 0
Study 2454893 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of vaccine at 15 months
Number of subjects: 0
Study 31939911 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Plus Resistance Training (150 min of moderate intensity aerobic activity and 2 days of resistance training per week)
Number of subjects: 0
Study 31939911 — intervention group
Group type: COMPARATOR
Intervention: Information only control group (monthly newsletters on type 2 diabetes education and prevention)
Number of subjects: 0
Study 31343582 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational telephone intervention
Number of subjects: 100
Study 31343582 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 100
Study 31343582 — intervention group
Group type: EXPERIMENTAL
Intervention: Per-protocol analysis of motivational telephone intervention
Number of subjects: 100
Study 31343582 — intervention group
Group type: COMPARATOR
Intervention: Per-protocol analysis of standard of care (control)
Number of subjects: 100
Study 28680370 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO + AO
Number of subjects: 60
Study 28680370 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO
Number of subjects: 60
Study 28680370 — intervention group
Group type: COMPARATOR
Intervention: CHO
Number of subjects: 60
Study 25869875 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (90 min, twice a week for 12 weeks)
Number of subjects: 200
Study 21212064 — intervention group
Group type: EXPERIMENTAL
Intervention: CD‐ROM aid
Number of subjects: 239
Study 21212064 — intervention group
Group type: COMPARATOR
Intervention: Brief description of the test (Control)
Number of subjects: 239
Study 18788531 — intervention group
Group type: EXPERIMENTAL
Intervention: Beijing Hypertensive No. 0
Number of subjects: 4000
Study 18788531 — intervention group
Group type: COMPARATOR
Intervention: Other antihypertensive drugs (Control)
Number of subjects: 4000
Study 15893416 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (2x400 mg po daily)
Number of subjects: 26
Study 15893416 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (1000 mg/m2 weekly)
Number of subjects: 26
Study 12610034 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical model
Number of subjects: 465
Study 12610034 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-h glucose
Number of subjects: 465
Study 12610034 — intervention group
Group type: COMPARATOR
Intervention: FPG
Number of subjects: 465
Study 11063900 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal replacement therapy (HRT)
Number of subjects: 2016
Study 9359745 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy (zidovudine, didanosine, nevirapine)
Number of subjects: 15
Study 8229656 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) treatment group
Number of subjects: 0
Study 8229656 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (ZDV) treatment group
Number of subjects: 0
Study 6495086 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric aspiration in erect position
Number of subjects: 15
Study 6495086 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric aspiration in supine position
Number of subjects: 15
Study 6495086 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-hour gastric aspirates
Number of subjects: 15
Study 6495086 — intervention group
Group type: COMPARATOR
Intervention: Posture change (erect vs supine)
Number of subjects: 15
Study 6495086 — intervention group
Group type: COMPARATOR
Intervention: Gallbladder contraction stimulated by intravenous pancreozymin
Number of subjects: 15
Study 31300280 — intervention group
Group type: EXPERIMENTAL
Intervention: Advax-adjuvanted honeybee venom immunotherapy (HBVIT)
Number of subjects: 27
Study 31300280 — intervention group
Group type: COMPARATOR
Intervention: Honeybee venom immunotherapy (VIT) without Advax adjuvant
Number of subjects: 27
Study 28940207 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective primes with three levels of working-memory load during prime processing.
Number of subjects: 47
Study 28940207 — intervention group
Group type: EXPERIMENTAL
Intervention: High cognitive load during prime processing.
Number of subjects: 47
Study 28940207 — intervention group
Group type: EXPERIMENTAL
Intervention: Low stimulus value indicated by medial-frontal negativity.
Number of subjects: 47
Study 27287343 — intervention group
Group type: EXPERIMENTAL
Intervention: Active PEMF treatment
Number of subjects: 8
Study 27287343 — intervention group
Group type: COMPARATOR
Intervention: Inactive PEMF (placebo)
Number of subjects: 8
Study 24964759 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous CCRT (n = 80)
Number of subjects: 158
Study 24964759 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial CCRT (n = 78)
Number of subjects: 158
Study 24964759 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 158
Study 20843245 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium besylate (178 patients)
Number of subjects: 340
Study 20843245 — intervention group
Group type: COMPARATOR
Intervention: Placebo (162 patients)
Number of subjects: 340
Study 20843245 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium besylate
Number of subjects: 340
Study 20843245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study 20843245 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium besylate and Placebo
Number of subjects: 340
Study 15486066 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX-4h (methotrexate as intravenous infusion over 4 hours)
Number of subjects: 505
Study 15486066 — intervention group
Group type: COMPARATOR
Intervention: MTX-24h (methotrexate as intravenous infusion over 24 hours)
Number of subjects: 505
Study 15486066 — intervention group
Group type: COMPARATOR
Intervention: MTX 1 g/m(2) (in NHL-BFM95)
Number of subjects: 505
Study 15486066 — intervention group
Group type: COMPARATOR
Intervention: MTX 5 g/m(2) (in NHL-BFM90)
Number of subjects: 505
Study 15486066 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX-4h
Number of subjects: 505
Study 11443161 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithyroid drug pretreatment
Number of subjects: 42
Study 11443161 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment
Number of subjects: 42
Study 9537629 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing breakfast to students at school
Number of subjects: 2
Study 9537629 — intervention group
Group type: COMPARATOR
Intervention: Better-organized schools
Number of subjects: 2
Study 9537629 — intervention group
Group type: COMPARATOR
Intervention: Poorly organized schools
Number of subjects: 2
Study 7517239 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 200/0.5 10%
Number of subjects: 100
Study 7517239 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl solution
Number of subjects: 100
Study 2511910 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 200 mg three times daily
Number of subjects: 7
Study 2511910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 1127088 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg calcium/kg (calcium gluconate at 3 ml/min for 3 h followed by normal saline for the fourth hour)
Number of subjects: 9
Study 1127088 — intervention group
Group type: COMPARATOR
Intervention: Normal saline at 3 ml/min for 4 h
Number of subjects: 9
Study 1127088 — intervention group
Group type: EXPERIMENTAL
Intervention: l-dopa (500 mg oral dose) during normal saline and calcium infusions
Number of subjects: 9
Study 31732868 — intervention group
Group type: EXPERIMENTAL
Intervention: Main meal dominant pattern (3 main eating occasions + 0-3 snacks)
Number of subjects: 143
Study 31732868 — intervention group
Group type: EXPERIMENTAL
Intervention: Snack dominant pattern (3 main eating occasions + >3 snacks)
Number of subjects: 143
Study 31732868 — intervention group
Group type: EXPERIMENTAL
Intervention: Large meal dominant pattern (≤2 main eating occasions + <2 snacks)
Number of subjects: 143
Study 31732868 — intervention group
Group type: EXPERIMENTAL
Intervention: Main meal dominant pattern
Number of subjects: 143
Study 28816033 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 mg bilayer sustained-release acetaminophen (APAP)
Number of subjects: 14
Study 28816033 — intervention group
Group type: COMPARATOR
Intervention: 1000 mg immediate-release acetaminophen (APAP) taken 6 hours apart
Number of subjects: 14
Study 28816033 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 mg single-layer sustained-release acetaminophen (APAP)
Number of subjects: 14
Study 28816033 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 mg single-layer sustained-release acetaminophen (APAP) with different excipient
Number of subjects: 14
Study 28816033 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 mg enteric-coated sustained-release acetaminophen (APAP) with fast-dissolving IR APAP
Number of subjects: 14
Study 27481125 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (400μg vaginally, 12h before procedure)
Number of subjects: 76
Study 27481125 — intervention group
Group type: COMPARATOR
Intervention: Bladder distension (1 litre of water, 2h before procedure)
Number of subjects: 76
Study 24114402 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intervention (HI) group
Number of subjects: 44
Study 24114402 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) group
Number of subjects: 44
Study 23176993 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 5% administered over 1 min (fast) in Group F
Number of subjects: 60
Study 23176993 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 5% administered over 3 min (slow) in Group S
Number of subjects: 60
Study 20571979 — intervention group
Group type: EXPERIMENTAL
Intervention: LY-2140023
Number of subjects: 0
Study 20571979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18691986 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of ketotifen fumarate ophthalmic solution 0.025%
Number of subjects: 108
Study 18691986 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference formulation of ketotifen fumarate ophthalmic solution 0.025%
Number of subjects: 108
Study 18691986 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inactive vehicle)
Number of subjects: 108
Study 16279896 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatobiliary randomized clinical trials
Number of subjects: 530
Study 16583968 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary surgical contraception (VSC)
Number of subjects: 0
Study 16583968 — intervention group
Group type: COMPARATOR
Intervention: Vasectomy (control group)
Number of subjects: 0
Study 10461002 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminaria tent insertion followed by ethacridine lactate (Rivanol) instillation (n = 34)
Number of subjects: 91
Study 10461002 — intervention group
Group type: COMPARATOR
Intervention: Nelathon catheter-condom method (n = 50)
Number of subjects: 91
Study 8923016 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemopreventive agents
Number of subjects: 0
Study 8923016 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 1800929 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 2% cyclosporine
Number of subjects: 20
Study 1800929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6625962 — intervention group
Group type: EXPERIMENTAL
Intervention: Active dialysis
Number of subjects: 10
Study 6625962 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 10
Study 31662969 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic training (IHT)
Number of subjects: 14
Study 31662969 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 14
Study 30075806 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief CETA (5 sessions)
Number of subjects: 0
Study 30075806 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard CETA (8-12 sessions)
Number of subjects: 0
Study 30075806 — intervention group
Group type: COMPARATOR
Intervention: Brief CETA and Standard CETA
Number of subjects: 0
Study 30075806 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study 26786589 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 48
Study 26786589 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 48
Study 24368753 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS duration ≥ 120 ms
Number of subjects: 3804
Study 24368753 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS duration 90-119 ms
Number of subjects: 3804
Study 24368753 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS duration ≥ 120 ms with heart failure (HF)
Number of subjects: 3804
Study 24368753 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS duration ≥ 120 ms without heart failure (HF)
Number of subjects: 3804
Study 24368753 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS duration 90-119 ms with heart failure (HF)
Number of subjects: 3804
Study 24368753 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS duration 90-119 ms without heart failure (HF)
Number of subjects: 3804
Study 22315155 — intervention group
Group type: EXPERIMENTAL
Intervention: leuprolide 3.75 mg
Number of subjects: 60
Study 22315155 — intervention group
Group type: EXPERIMENTAL
Intervention: leuprolide 7.5 mg
Number of subjects: 60
Study 22315155 — intervention group
Group type: EXPERIMENTAL
Intervention: goserelin 3.6 mg
Number of subjects: 60
Study 20018365 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 microg, 15 microg, or 30 microg haemagglutinin vaccine
Number of subjects: 1173
Study 20018365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1173
Study 17394665 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 minutes of moderate intensity exercise
Number of subjects: 8
Study 17394665 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control)
Number of subjects: 8
Study 15809123 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic bupivacaine (2.5 mg) + fentanyl (25 microg)
Number of subjects: 67